Bank Hapoalim BM Raises Stake in Novo Nordisk A/S $NVO

Bank Hapoalim BM boosted its position in Novo Nordisk A/S (NYSE:NVO) by 23.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,750 shares of the company’s stock after buying an additional 5,215 shares during the quarter. Bank Hapoalim BM’s holdings in Novo Nordisk A/S were worth $1,915,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Copeland Capital Management LLC boosted its stake in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after buying an additional 255 shares in the last quarter. North Capital Inc. purchased a new stake in Novo Nordisk A/S in the first quarter worth approximately $27,000. Stone House Investment Management LLC purchased a new stake in Novo Nordisk A/S in the first quarter worth approximately $30,000. Disciplina Capital Management LLC boosted its stake in Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 297 shares in the last quarter. Finally, Spirit of America Management Corp NY purchased a new stake in Novo Nordisk A/S in the first quarter worth approximately $35,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $59.68 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company has a market cap of $266.45 billion, a PE ratio of 16.39, a P/E/G ratio of 2.25 and a beta of 0.68. The business has a 50 day moving average of $54.92 and a 200 day moving average of $63.84. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $120.56.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The company had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio is currently 22.53%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on NVO shares. BNP Paribas Exane upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price objective for the company in a research report on Wednesday, August 13th. Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. BNP Paribas upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Novo Nordisk A/S in a research report on Saturday, September 27th. Finally, HSBC set a $70.00 price objective on Novo Nordisk A/S in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $77.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.